Plasma Fibrinogen and Silent Cerebrovascular Lesions
[Background and purpose] Silent cerebrovascular lesions are associated with an increased risk of stroke. Although the incidence of cerebral hemorrhage has decreased in Japan, prevalence of cerebral infarction has not decreased. Fibrinogen is a major determinant of plasma viscosity. It is possible th...
Saved in:
| Published in | Japanese Journal of Cardiovascular Disease Prevention Vol. 40; no. 3; pp. 181 - 189 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
The Japanese Association for Cerebro-cardiovascular Disease Control
2005
社団法人 日本循環器管理研究協議会 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1346-6267 |
| DOI | 10.11381/jjcdp2001.40.181 |
Cover
| Abstract | [Background and purpose] Silent cerebrovascular lesions are associated with an increased risk of stroke. Although the incidence of cerebral hemorrhage has decreased in Japan, prevalence of cerebral infarction has not decreased. Fibrinogen is a major determinant of plasma viscosity. It is possible that elevated fibrinogen level is associated with the risk of cerebral infarction. We conducted a cross-sectional study to determine the association between plasma fibrinogen and cerebrovascular lesions in a general population. [Methods] The study population consisted of 662 subjects (32.2% men, mean age 66.6 ± 5.3 years, mean plasma fibrinogen 299.8 ± 63.5 mg/dl) from a general population of rural Japanese community, Ohasama. We evaluated the association between plasma fibrinogen and silent cerebrovascular lesions [number of lacunar infarction and extent of periventricular hyperintensity (PVH)] detected by MRI. [Results] Fibrinogen levels were significantly higher in subjects with multiple lacunar infarctions. Each 1SD (63.5 mg/dl) increase in fibrinogen was significantly associated with an increase in the risk of lacunar infarction (OR=1.29, 95% CI : 1.09-1.53) after adjustment for age, sex, smoking status, drinking status, use of antihypertensive medication, BMI, 24-h ambulatory blood pressure (24-h ABP), and a history of hypercholesterolemia, diabetes mellitus or atrial fibrillation. Twenty-four hour ABP was also significantly and independently associated with lacunar infarction. Even when 24-h ABP values were within the normal range (<135/80 mmHg), elevated fibrinogen levels were associated with an increased risk of lacunar infarction. There was no association between fibrinogen and PVH. [Conclusion] The present results demonstrated that fibrinogen was strongly associated with risk of lacunar infarction, suggesting that fibrinogen is an independent risk factor or predictor for lacunar infarction. |
|---|---|
| AbstractList | [Background and purpose] Silent cerebrovascular lesions are associated with an increased risk of stroke. Although the incidence of cerebral hemorrhage has decreased in Japan, prevalence of cerebral infarction has not decreased. Fibrinogen is a major determinant of plasma viscosity. It is possible that elevated fibrinogen level is associated with the risk of cerebral infarction. We conducted a cross-sectional study to determine the association between plasma fibrinogen and cerebrovascular lesions in a general population.[Methods] The study population consisted of 662 subjects (32.2% men, mean age 66.6 ± 5.3 years, mean plasma fibrinogen 299.8 ± 63.5 mg/dl) from a general population of rural Japanese community, Ohasama. We evaluated the association between plasma fibrinogen and silent cerebrovascular lesions [number of lacunar infarction and extent of periventricular hyperintensity (PVH)] detected by MRI.[Results] Fibrinogen levels were significantly higher in subjects with multiple lacunar infarctions. Each 1SD (63.5 mg/dl) increase in fibrinogen was significantly associated with an increase in the risk of lacunar infarction (OR=1.29, 95% CI : 1.09-1.53) after adjustment for age, sex, smoking status, drinking status, use of antihypertensive medication, BMI, 24-h ambulatory blood pressure (24-h ABP), and a history of hypercholesterolemia, diabetes mellitus or atrial fibrillation. Twenty-four hour ABP was also significantly and independently associated with lacunar infarction. Even when 24-h ABP values were within the normal range (<135/80 mmHg), elevated fibrinogen levels were associated with an increased risk of lacunar infarction. There was no association between fibrinogen and PVH.[Conclusion] The present results demonstrated that fibrinogen was strongly associated with risk of lacunar infarction, suggesting that fibrinogen is an independent risk factor or predictor for lacunar infarction.
【背景・目的】無症候性脳血管障害は脳卒中の高危険群であると考えられている。降圧療法の進歩とともに脳出血発症は減少してきたが、脳梗塞の有病率は依然として高率である。このような状況は、既知の主要な危険因子のコントロールだけは不十分であることを示唆しており、脳卒中に関する他の危険因子の発見・コントロールが必要と考えられる。フィブリノーゲンは血液粘度の主要な決定因子であり、フィブリノーゲン高値は脳梗塞リスクと関連している可能性がある。本研究は、一般住民において、フィブリノーゲンと無症候性脳血管障害 [ラクナ梗塞および脳室周囲高信号域 (PVH)] との関連を明らかにすることを目的とした。【方法】岩手県大迫町の55歳以上の一般住民で頭部MRIを撮影した662人 (平均年齢66.6±5.3歳、男性32%) を対象に、フィブリノーゲンと無症候性脳血管障害との関連を横断的に検討した。【結果】ラクナ梗塞の数が多い群ほど、フィブリノーゲン値は有意に高値であった (P=0.0008) 。各種危険因子で補正後も、フィブリノーゲンの1SD (63.5mg/dl) 上昇ごとのラクナ梗塞のオッズ比は1.29 (P=0.004) と有意であった。また、フィブリノーゲンと24時間自由行動下血圧はそれぞれ独立してラクナ梗塞と関連しており、両方高値の群 (フィブリノーゲン≧332mg/dlかつ24時間自由行動下血圧≧135/80mmHg) ではラクナ梗塞を有するオッズ比が2.50倍と著しく高値であった。フィブリノーゲンとPVHに関連は認められなかった。【結論】本研究からフィブリノーゲンとラクナ梗塞との関連が示唆された。フィブリノーゲンはラクナ梗塞の危険因子あるいは予測因子として応用の可能性があると考えられる。 [Background and purpose] Silent cerebrovascular lesions are associated with an increased risk of stroke. Although the incidence of cerebral hemorrhage has decreased in Japan, prevalence of cerebral infarction has not decreased. Fibrinogen is a major determinant of plasma viscosity. It is possible that elevated fibrinogen level is associated with the risk of cerebral infarction. We conducted a cross-sectional study to determine the association between plasma fibrinogen and cerebrovascular lesions in a general population. [Methods] The study population consisted of 662 subjects (32.2% men, mean age 66.6 ± 5.3 years, mean plasma fibrinogen 299.8 ± 63.5 mg/dl) from a general population of rural Japanese community, Ohasama. We evaluated the association between plasma fibrinogen and silent cerebrovascular lesions [number of lacunar infarction and extent of periventricular hyperintensity (PVH)] detected by MRI. [Results] Fibrinogen levels were significantly higher in subjects with multiple lacunar infarctions. Each 1SD (63.5 mg/dl) increase in fibrinogen was significantly associated with an increase in the risk of lacunar infarction (OR=1.29, 95% CI : 1.09-1.53) after adjustment for age, sex, smoking status, drinking status, use of antihypertensive medication, BMI, 24-h ambulatory blood pressure (24-h ABP), and a history of hypercholesterolemia, diabetes mellitus or atrial fibrillation. Twenty-four hour ABP was also significantly and independently associated with lacunar infarction. Even when 24-h ABP values were within the normal range (<135/80 mmHg), elevated fibrinogen levels were associated with an increased risk of lacunar infarction. There was no association between fibrinogen and PVH. [Conclusion] The present results demonstrated that fibrinogen was strongly associated with risk of lacunar infarction, suggesting that fibrinogen is an independent risk factor or predictor for lacunar infarction. |
| Author | Hara, Azusa Shintani, Yoriko Kondo, Takeo Inoue, Ryusuke Ohkubo, Takayoshi Obara, Taku Izumi, Shin-Ichi Metoki, Hirohito Asayama, Kei Imai, Yutaka Hoshi, Haruhisa Aono, Yoko Hashimoto, Junichiro Kikuya, Masahiro Totsune, Kazuhito Satoh, Hiroshi |
| Author_FL | 目時 弘仁 出江 伸一 大久保 孝義 星 晴久 Satoh Hiroshi Aono Yoko Shintani Yoriko 井上 隆輔 小原 拓 Hara Azusa Hashimoto Junichiro 近藤 健男 今井 潤 戸恒 和人 菊谷 昌浩 浅山 敬 |
| Author_FL_xml | – sequence: 1 fullname: Aono Yoko – sequence: 2 fullname: 菊谷 昌浩 – sequence: 3 fullname: Hara Azusa – sequence: 4 fullname: 大久保 孝義 – sequence: 5 fullname: 近藤 健男 – sequence: 6 fullname: 浅山 敬 – sequence: 7 fullname: 井上 隆輔 – sequence: 8 fullname: 目時 弘仁 – sequence: 9 fullname: 小原 拓 – sequence: 10 fullname: Shintani Yoriko – sequence: 11 fullname: Hashimoto Junichiro – sequence: 12 fullname: 戸恒 和人 – sequence: 13 fullname: 星 晴久 – sequence: 14 fullname: Satoh Hiroshi – sequence: 15 fullname: 出江 伸一 – sequence: 16 fullname: 今井 潤 |
| Author_xml | – sequence: 1 fullname: Asayama, Kei organization: Clinical Pharmacology and Therapeutics – sequence: 1 fullname: Hoshi, Haruhisa organization: Ohasama Hospital, Iwate, Japan – sequence: 1 fullname: Ohkubo, Takayoshi organization: Tohoku University 21st Century COE Program Comprehensive Research and Education Center for Planning of Drug Development and Clinical Evaluation – sequence: 1 fullname: Hara, Azusa organization: Clinical Pharmacology and Therapeutics – sequence: 1 fullname: Inoue, Ryusuke organization: Tohoku University 21st Century COE Program Comprehensive Research and Education Center for Planning of Drug Development and Clinical Evaluation – sequence: 1 fullname: Totsune, Kazuhito organization: Tohoku University 21st Century COE Program Comprehensive Research and Education Center for Planning of Drug Development and Clinical Evaluation – sequence: 1 fullname: Satoh, Hiroshi organization: Environmental Health Science, Tohoku University Graduate School of Pharmaceutical Science and Medicine, Sendai, Japan – sequence: 1 fullname: Kondo, Takeo organization: Physical Medicine and Rehabilitation – sequence: 1 fullname: Metoki, Hirohito organization: Clinical Pharmacology and Therapeutics – sequence: 1 fullname: Izumi, Shin-Ichi organization: Physical Medicine and Rehabilitation – sequence: 1 fullname: Imai, Yutaka organization: Tohoku University 21st Century COE Program Comprehensive Research and Education Center for Planning of Drug Development and Clinical Evaluation – sequence: 1 fullname: Kikuya, Masahiro organization: Planning for Drug Development and Clinical Evaluation – sequence: 1 fullname: Shintani, Yoriko organization: Clinical Pharmacology and Therapeutics – sequence: 1 fullname: Obara, Taku organization: Clinical Pharmacology and Therapeutics – sequence: 1 fullname: Aono, Yoko organization: Clinical Pharmacology and Therapeutics – sequence: 1 fullname: Hashimoto, Junichiro organization: Tohoku University 21st Century COE Program Comprehensive Research and Education Center for Planning of Drug Development and Clinical Evaluation |
| BackLink | https://cir.nii.ac.jp/crid/1390282680155882752$$DView record in CiNii |
| BookMark | eNo9kE9LAzEUxHOoYNV-AG978Lo1L3822aOUVoWCgnoOr8nbmmWbLUkV_PZWKr38BmaGOcwVm6QxEWO3wOcA0sJ93_uwF5zDXB0tCxM2BamauhGNuWSzUnrOuRSyFUZNmXodsOywWsVNjmncUqowheotDpQO1YIybfL4jcV_DZirNZU4pnLDLjocCs3-9Zp9rJbvi6d6_fL4vHhY1z0oK2qyHQWjWwTPm0YFUtyAIEXgA3RoDAYSQnFU6IPqhEXVmVaLAKBDqzfymt2ddlOMzsc_gmy5sKKxHLS2VhgtjrXlqdaXA27J7XPcYf5xmA_RD-TOjzjFnTzheMw595-YHSX5C9ikXz8 |
| ContentType | Journal Article |
| Copyright | The Japanese Association for Cerebro-cardiovascular Disease Control |
| Copyright_xml | – notice: The Japanese Association for Cerebro-cardiovascular Disease Control |
| DBID | RYH |
| DOI | 10.11381/jjcdp2001.40.181 |
| DatabaseName | CiNii Complete |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | 血しょうフィブリノーゲン値と無症候性脳血管障害との関連大迫研究 |
| DocumentTitle_FL | 血しょうフィブリノーゲン値と無症候性脳血管障害との関連大迫研究 |
| EndPage | 189 |
| ExternalDocumentID | 130003662116 article_jjcdp2001_40_3_40_3_181_article_char_en |
| GroupedDBID | ABJNI ALMA_UNASSIGNED_HOLDINGS JSP KQ8 MOJWN RJT RYH |
| ID | FETCH-LOGICAL-j1482-e8fed759a1c0664de40712e4e1cd1fa77ade2240a4acd4f28a4f7952d115d95b3 |
| ISSN | 1346-6267 |
| IngestDate | Thu Jun 26 22:33:35 EDT 2025 Wed Sep 03 06:29:17 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Issue | 3 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j1482-e8fed759a1c0664de40712e4e1cd1fa77ade2240a4acd4f28a4f7952d115d95b3 |
| ORCID | 0000-0002-3080-6107 0000-0002-3283-8196 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jjcdp2001/40/3/40_3_181/_article/-char/en |
| PageCount | 9 |
| ParticipantIDs | nii_cinii_1390282680155882752 jstage_primary_article_jjcdp2001_40_3_40_3_181_article_char_en |
| PublicationCentury | 2000 |
| PublicationDate | 2005 |
| PublicationDateYYYYMMDD | 2005-01-01 |
| PublicationDate_xml | – year: 2005 text: 2005 |
| PublicationDecade | 2000 |
| PublicationTitle | Japanese Journal of Cardiovascular Disease Prevention |
| PublicationTitleAlternate | JJCDP |
| PublicationTitle_FL | 日本循環器病予防学会誌 JJCDP 日循予防誌 |
| PublicationYear | 2005 |
| Publisher | The Japanese Association for Cerebro-cardiovascular Disease Control 社団法人 日本循環器管理研究協議会 |
| Publisher_xml | – name: The Japanese Association for Cerebro-cardiovascular Disease Control – name: 社団法人 日本循環器管理研究協議会 |
| References | 11) Yarnell JWG, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity and white blood cell count are major risk factor for ischemic heart disease : The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991 ; 83 : 836-844. 8) Ernst E, Resch KL. Fibrinogen as cardiovascular risk factor : a meta-analysis and review of literature. Ann Intern Med 1993 ; 118 : 956-963. 34) Kobayashi S, Okada K, Koide H, et al. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 1997 ; 28 : 1932-1939. 14) Di Minno G, Mancini M : Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis 1990 ; 10 : 1-7. 29) 日本高血圧学会.高血圧治療ガイドライン 2004. 4) Drouet L. Fibrinogen : a treatable risk factor? Cerebrovasc Dis 1996 ; 6 : 2-6. 10) Grotta JC, Vital D, Alam R, et al. Prediction of carotid stenosis progression by lipid and haematologic measurements. Neurology 1989 ; 39 : 1325-1331. 3) 厚生統計協会.国民衛生の動向.厚生の指標 (臨時増刊). 2002; 49; 388-389. 32) Lee AJ, Smith WC, Lowe GD, et al. Plasma fibrinogen and coronary risk factors : the Scottish Heart Health Study. J Clin Epidemiol. 1990 ; 43 : 913-9. 25) Hozawa A, Ohkubo T, Nagai K, et al. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home : the Ohasama study. Arch Intern Med 2000 ; 160 : 3301-3306. 12) Kannel WB, Wolf PA, Castelli WP, et al. Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA 1987 ; 258 : 1183-1186. 36) Schmidt R, Fazekas F, Kapeller P, et al. MRI white matter hyperintensities : three-year follow-up of the Austrian Stroke Prevention Study. Neurology 1999; 53 : 132-139. 16) Moons KG, Bots ML, Salonen JT, et al. Prediction of stroke in general population in Europe (EUROSTROKE) : Is there a role for fibrinogen and electrocardiography? J Epidemiol Community Health 2002 ; 56 Suppl 1 : 30-6. 30) Folsom AR, Rosamond WD, Shahar E, et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999 ; 100 : 736-742. 5) Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997 ; 54 (suppl 3) : 32-40. 31) Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor : a meta-analysis and review of the literature. Ann Intern Med. 1993 ; 118 : 956-63. 26) Imai Y, Ohkubo T, Hozawa A, et al. Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebocontrolled open trial. J Hypertens 2001 ; 19 : 179-185. 13) Whilelmsen L, Svardsudd K, Korsan-Bengsten K, et al. Fibrinogen as risk factor for stroke and myocardial infarction. N Engl J Med 1984 ; 311 : 501-505. 21) Marti-Fabregas J, Valencia C, Pujol J, et al. Fibrinogen and the amount of leukoaraiosis in patients with symptomatic small-vessel disease. Eur Neurol 2002 ; 48 : 185-190. 23) Imai Y, Satoh H, Nagai K, et al. Characteristics of a community-based distribution of home bloodpressure in Ohasama in northern Japan. J Hypertens 1993 ; 11 : 1441-1449. 35) Qizilbash N, Jones L, Warlow C, et al. Fibrinogen and lipid concentrations as risk factor for transient ischemic attacks and minor ischemic stroke. BMJ 1991 ; 303 : 605-609. 33) 日本脳卒中学会.脳卒中治療ガイドライン 2004. 9) Maresca G, Di Blasio A, Marchioli R, et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscler Thromb Vas Biol 1999 ; 19 : 1368-1377. 28) SC Kofoed, HH Wittrup, H Sillesen, et al. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques : the Copenhagen City Heart Study. Eur Heart J 2003 ; 24 : 567-76. 24) Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement : a population-based observation in Ohasama, Japan. J Hypertens 1998 ; 16 : 971-975. 22) Ding J, Nieto FJ, Beauchamp NJ, et al. A prospective analysis of risk factors for white matter disease in the brain stem : the Cardiovascular Health Study. Neuroepidemiology 2003 ; 22 : 275-282. 15) Rothwell PM, Howard SC, Power DA, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic. stroke 2004 ; 35 : 2300-2305. 17) S.C. Kofoed, H.H. Wittrup, H. Sillesen, et al. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques : The Copenhagen City Heart Study. Eur Heart Journal 2003 ; 24 : 567-576. 19) Schmidt R, Fazekas F, Hayn M, et al. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. J Neurol Sci 1997 ; 152 : 15-21. 7) Iwamoto T, Kubo H, Takasaki M. Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's disease. Stroke 1995 ; 26 : 52-56. 27) Fazekas F, Niederkorn K, Schmidt R, et al. White matter signal abnormalities in normal individuals : correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke 1988 ; 19 : 1285-1288. 1) Vermeer SE, Den Heijer T, Koudstaal PJ, et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003 ; 34 : 392-396. 20) Tsuda Y, Satoh K, Kitadai M, et al. Hemorheologic profiles of plasma fibrinogen and blood viscosity from silent to acute and chronic cerebral infarctions. J Neurol Sci 1997 ; 147 : 49-54. 2) 厚生統計協会.国民衛生の動向.厚生の指標 (臨時増刊). 2001; 48. 18) Sato S, Nakamura M, Iida M, et al. Plasma fibrinogen and coronary heart disease in urban Japanese. Am J Epidemiol 2000 ; 152 : 420-423. 6) Fisher M, Meiselman HJ. Hemorheological factor in cerebral ischemia. Stroke 1991 ; 22 : 1164-1169. |
| References_xml | – reference: 15) Rothwell PM, Howard SC, Power DA, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic. stroke 2004 ; 35 : 2300-2305. – reference: 9) Maresca G, Di Blasio A, Marchioli R, et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscler Thromb Vas Biol 1999 ; 19 : 1368-1377. – reference: 12) Kannel WB, Wolf PA, Castelli WP, et al. Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA 1987 ; 258 : 1183-1186. – reference: 32) Lee AJ, Smith WC, Lowe GD, et al. Plasma fibrinogen and coronary risk factors : the Scottish Heart Health Study. J Clin Epidemiol. 1990 ; 43 : 913-9. – reference: 34) Kobayashi S, Okada K, Koide H, et al. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 1997 ; 28 : 1932-1939. – reference: 6) Fisher M, Meiselman HJ. Hemorheological factor in cerebral ischemia. Stroke 1991 ; 22 : 1164-1169. – reference: 18) Sato S, Nakamura M, Iida M, et al. Plasma fibrinogen and coronary heart disease in urban Japanese. Am J Epidemiol 2000 ; 152 : 420-423. – reference: 14) Di Minno G, Mancini M : Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis 1990 ; 10 : 1-7. – reference: 8) Ernst E, Resch KL. Fibrinogen as cardiovascular risk factor : a meta-analysis and review of literature. Ann Intern Med 1993 ; 118 : 956-963. – reference: 27) Fazekas F, Niederkorn K, Schmidt R, et al. White matter signal abnormalities in normal individuals : correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke 1988 ; 19 : 1285-1288. – reference: 1) Vermeer SE, Den Heijer T, Koudstaal PJ, et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003 ; 34 : 392-396. – reference: 22) Ding J, Nieto FJ, Beauchamp NJ, et al. A prospective analysis of risk factors for white matter disease in the brain stem : the Cardiovascular Health Study. Neuroepidemiology 2003 ; 22 : 275-282. – reference: 28) SC Kofoed, HH Wittrup, H Sillesen, et al. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques : the Copenhagen City Heart Study. Eur Heart J 2003 ; 24 : 567-76. – reference: 30) Folsom AR, Rosamond WD, Shahar E, et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999 ; 100 : 736-742. – reference: 19) Schmidt R, Fazekas F, Hayn M, et al. Risk factors for microangiopathy-related cerebral damage in the Austrian stroke prevention study. J Neurol Sci 1997 ; 152 : 15-21. – reference: 25) Hozawa A, Ohkubo T, Nagai K, et al. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home : the Ohasama study. Arch Intern Med 2000 ; 160 : 3301-3306. – reference: 31) Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor : a meta-analysis and review of the literature. Ann Intern Med. 1993 ; 118 : 956-63. – reference: 17) S.C. Kofoed, H.H. Wittrup, H. Sillesen, et al. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques : The Copenhagen City Heart Study. Eur Heart Journal 2003 ; 24 : 567-576. – reference: 33) 日本脳卒中学会.脳卒中治療ガイドライン 2004. – reference: 29) 日本高血圧学会.高血圧治療ガイドライン 2004. – reference: 3) 厚生統計協会.国民衛生の動向.厚生の指標 (臨時増刊). 2002; 49; 388-389. – reference: 23) Imai Y, Satoh H, Nagai K, et al. Characteristics of a community-based distribution of home bloodpressure in Ohasama in northern Japan. J Hypertens 1993 ; 11 : 1441-1449. – reference: 11) Yarnell JWG, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity and white blood cell count are major risk factor for ischemic heart disease : The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991 ; 83 : 836-844. – reference: 35) Qizilbash N, Jones L, Warlow C, et al. Fibrinogen and lipid concentrations as risk factor for transient ischemic attacks and minor ischemic stroke. BMJ 1991 ; 303 : 605-609. – reference: 36) Schmidt R, Fazekas F, Kapeller P, et al. MRI white matter hyperintensities : three-year follow-up of the Austrian Stroke Prevention Study. Neurology 1999; 53 : 132-139. – reference: 7) Iwamoto T, Kubo H, Takasaki M. Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's disease. Stroke 1995 ; 26 : 52-56. – reference: 20) Tsuda Y, Satoh K, Kitadai M, et al. Hemorheologic profiles of plasma fibrinogen and blood viscosity from silent to acute and chronic cerebral infarctions. J Neurol Sci 1997 ; 147 : 49-54. – reference: 24) Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement : a population-based observation in Ohasama, Japan. J Hypertens 1998 ; 16 : 971-975. – reference: 4) Drouet L. Fibrinogen : a treatable risk factor? Cerebrovasc Dis 1996 ; 6 : 2-6. – reference: 2) 厚生統計協会.国民衛生の動向.厚生の指標 (臨時増刊). 2001; 48. – reference: 10) Grotta JC, Vital D, Alam R, et al. Prediction of carotid stenosis progression by lipid and haematologic measurements. Neurology 1989 ; 39 : 1325-1331. – reference: 26) Imai Y, Ohkubo T, Hozawa A, et al. Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebocontrolled open trial. J Hypertens 2001 ; 19 : 179-185. – reference: 13) Whilelmsen L, Svardsudd K, Korsan-Bengsten K, et al. Fibrinogen as risk factor for stroke and myocardial infarction. N Engl J Med 1984 ; 311 : 501-505. – reference: 16) Moons KG, Bots ML, Salonen JT, et al. Prediction of stroke in general population in Europe (EUROSTROKE) : Is there a role for fibrinogen and electrocardiography? J Epidemiol Community Health 2002 ; 56 Suppl 1 : 30-6. – reference: 21) Marti-Fabregas J, Valencia C, Pujol J, et al. Fibrinogen and the amount of leukoaraiosis in patients with symptomatic small-vessel disease. Eur Neurol 2002 ; 48 : 185-190. – reference: 5) Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997 ; 54 (suppl 3) : 32-40. |
| SSID | ssj0003239274 ssib000872030 ssib005902230 ssib029852151 |
| Score | 1.4158773 |
| Snippet | [Background and purpose] Silent cerebrovascular lesions are associated with an increased risk of stroke. Although the incidence of cerebral hemorrhage has... |
| SourceID | nii jstage |
| SourceType | Publisher |
| StartPage | 181 |
| SubjectTerms | fibrinogen general population lacunar infarction periventricular hyperintensity (PVH) フィブリノーゲン ラクナ梗塞 一般住民 脳室周囲高信号域 (PVH) |
| Title | Plasma Fibrinogen and Silent Cerebrovascular Lesions |
| URI | https://www.jstage.jst.go.jp/article/jjcdp2001/40/3/40_3_181/_article/-char/en https://cir.nii.ac.jp/crid/1390282680155882752 |
| Volume | 40 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Japanese Journal of Cardiovascular Disease Prevention, 2005/10/31, Vol.40(3), pp.181-189 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library issn: 1346-6267 databaseCode: KQ8 dateStart: 20010101 customDbUrl: isFulltext: true dateEnd: 20071231 titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html omitProxy: true ssIdentifier: ssj0003239274 providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swECacdOlStGiLpm0KDeUkKI0oUiKXAIZjI-i7gANkEyiSgmUjVuDHkP6j_MvembIspwH6WAiZlASRd7777sEjIe-FNc7qwkaFRm-V5UkkC5ZGzBqlipi5wmdbfE0vLvnHK3HV6911spbWq-LE_HxwX8n_UBX6gK64S_YfKNu-FDrgGugLLVAY2r-i8XeAvtc6HGHa_ryG23wiZoWaJBy4Bdi7u1TTz27Z-ua2aBQ0JZ5AGXZg6WA_QfXcB3DCbamnXdSeDhVV51QxvJAZlcOQDiVVCZWKDgXtw1gbC_lUzda3Ovyil3pSLerdOwQ8R9UIHk1pn1HViqFvk9m6qMOxnunbejmp9twTomWlzda27TQ6vLZJn2yWIDIPz2ng0_Q7cjnhaQS2V9YV3L7OU8OgSUcKx_4UmEahx_6Mot91BYAVVBZTY28ws-yEQ-f2yb0S3BjyA02fgrGcHpBHDF0_GP__0UWyGM_uiD4F4Gj3mykpEFy17r-EATDN_JHLzdSamDt-1of7HwX4aArWApaBOJhXVQcCjZ-SJw2TBH3PiM9Ib6qfE-6ZMNgxYQBMGHgmDO4xYdAw4QtyORqOBxdRcxRHNMVCsZGTpbOZUDo2gFG5degHYI672Ni41FmmrUNwqLk2lpdMal5mSjALBodVokheksN5PXevSGCkU4CIRGqxdGOWSFPaROhTm0qdSFEekTM_1fzG11vJm_9X3i5Kzk_zxDewNu047lMEsXBEjmGJclNhCwYOehVSibYBWJOZYK__MP6GPN7U59342d6Sw9Vi7Y4Bea6Kdxua_wKOq3oA |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+Fibrinogen+and+Silent+Cerebrovascular+Lesions&rft.jtitle=Japanese+Journal+of+Cardiovascular+Disease+Prevention&rft.au=%E9%9D%92%E9%87%8E+%E8%93%89%E5%AD%90&rft.au=Kikuya+Masahiro&rft.au=%E5%8E%9F+%E6%A2%93&rft.au=Ohkubo+Takayoshi&rft.date=2005&rft.pub=The+Japanese+Association+for+Cerebro-cardiovascular+Disease+Control&rft.issn=1346-6267&rft.volume=40&rft.issue=3&rft.spage=181&rft.epage=189&rft_id=info:doi/10.11381%2Fjjcdp2001.40.181&rft.externalDocID=130003662116 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-6267&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-6267&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-6267&client=summon |